<DOC>
	<DOCNO>NCT00826059</DOCNO>
	<brief_summary>The primary objective study assess safety effectiveness SPG stimulation ISS patient acute ischemic stroke anterior circulation initiate within 24 hour stroke onset .</brief_summary>
	<brief_title>Implant Augmentation Cerebral Blood Flow Trial , Effectiveness Safety 24 Hour Window</brief_title>
	<detailed_description>A multi-center , multinational , randomize , double blind , sham control , adjunctive Standard Care , parallel arm study include ongoing DSMB review accumulate safety data . Screening : Since treatment initiate within 24 hour stroke onset , screen window limit procedure perform within window.Subjects Acute Ischemic Stroke screen upon arrival hospital . Since treatment initiate 8 24 hour stroke onset , screen window limit procedure perform soon possible . All screen patient identify patient number sign informed consent prior study procedure initiation . Period 1 : Day 1-5 : Day 1- Eligible subject randomize 1:1 ( ISS Stimulation : Sham Control ) ratio : - Group 1 : Implantation ISS Stimulation five consecutive day &amp; Standard Care - Group 2 : Sham Implantation Sham Stimulation five consecutive day &amp; Standard Care Subjects transfer implantation procedure facility implantation/sham implantation perform trained physician . Following implantation , stimulation/sham stimulation deliver . Day 2-4 ISS / Sham Stimulation repeat follow four consecutive day train personnel within 18-26 hour precede stimulation . Day 5 / Day Discharge . Following last ISS /Sham Stimulation , explantation perform patient evaluate safety effectiveness . Subjects continue Standard Care need release hospital upon investigator 's judgment . Period 2 : Day Discharge - 89±7 day During period group ( ISS Stimulation Sham Control ) treat accord Standard Care either hospital , rehabilitation center home . Scheduled visit perform day 30±7 day 60 ±7 , include safety effectiveness assessment . Final Visit Day 90±7 day : The final visit perform study site include safety effectiveness evaluation . Patients contact study personnel via telephone Day 180±7 Day 360±7 order ass quality life status .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>1 . Age : Between 40 year 80 year male 85 female subject 2 . Clinical diagnosis acute ischemic stroke Carotid , Middle Anterior Cerebral Artery territories 3 . Imaging finding demonstrate sign ischemia anterior circulation , consistent clinical diagnosis 4 . Baseline NIHSS ≥ 7 ≤ 18 within 2 hour prior implantation . 5 . Ability initiate treatment within 8 24 hour stroke onset 6 . Signed informed consent patient him/herself legally authorize representative applicable 1 . Intracranial hemorrhage hemorrhagic transformation 2 . Massive stroke 3 . Acute ischemic stroke posterior circulation 4 . Minor stroke 5 . Treated IVtPA , IAtPA neurothrombectomy device current stroke 6 . Previous stroke last 6 month preexist disability 7 . Patients bleed propensity condition oral cavity prevents implantation 8 . Clinical sign symptom image evidence bilateral stroke . 9 . Treated IVtPA , IAtPA neurothrombectomy device current stroke . 10 . Known cerebral arteriovenous malformation , cerebral aneurysm . 11 . Clinical suspicion septic embolus . 12 . Uncontrolled hypertension ( systolic &gt; 185 mmHg and/or diastolic &gt; 110 mmHg ) 13 . Serious systemic infection . 14 . Women know pregnant positive indeterminate pregnancy test . 15 . Patients implanted neural stimulator/ electronic device ( pacemaker ) . 16 . Life expectancy &lt; 1 year cause stroke .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>acute ischemic stroke</keyword>
	<keyword>randomize clinical trial</keyword>
	<keyword>effectiveness</keyword>
	<keyword>safety</keyword>
</DOC>